GeoVax Ebola vaccine successful in rodent models
The vaccine has provided Syrian golden hamsters and guinea pigs with 100 percent protection against Ebola virus infections.
"We are very pleased with the outcome of this study," Harriet L. Robinson, GeoVax's chief scientific officer, said. "Through our ongoing research, we have anticipated that GeoVax's [virus-like particles] would elicit a strong immune response, and we had already demonstrated the production of Ebola VLPs in human cells. The next steps will be vaccination and challenge studies in nonhuman primates while also preparing for cGMP manufacturing of the vaccine for human clinical trials."
The new vaccine implements a recombinant modified vaccinia Ankara vector to carry genetic sequences of the 2014 Ebola virus with express non-infectious virus-like particles.
"GeoVax is committed to developing an Ebola vaccine with a superior safety and efficacy profile as compared to those of other vaccine candidates under development," Robert T. McNally, GeoVax's president and CEO, said. "There are currently no approved vaccines for filoviruses (including Ebola virus) anywhere on the globe. The 2014/15 West African Ebola epidemic has caused over 28,000 infections, resulting in over 11,300 deaths. Considering the unpredictable and regular outbreaks of Ebola virus infections, the development of vaccines that broadly protect against multiple filoviruses is a global priority. We believe our Ebola vaccine candidates have the potential to provide support in this effort, and we look forward to updating our shareholders as we move ahead."